2017 Pediatric Rheumatology Symposium

May 17-20, 2017. Houston, Texas.

View by Number View by Title View Sessions

View by Date

Abstract Number: 151

Severe Phenotype of Mevalonate-kinase Deficiency in the Czech Republic
Abstract Number: 152

Characteristics of Patients With Juvenile Idiopathic Arthritis in a US Healthcare Claims Database
Abstract Number: 153

Training pediatric rheumatology fellows intra-articular injection techniques and skills using a cadaver based musculoskeletal curriculum
Abstract Number: 154

“Celebrate Ability”: Structured Art Workshop as a Therapeutic Coping Strategy for Patients with Juvenile Idiopathic Arthritis
Abstract Number: 155

A Single Center Review of Health Related Quality of Life in Children with Systemic Lupus Erythematosus Using the Pediatric Quality of Life Inventory Version 4.0 Generic Core Scale
Abstract Number: 156

Teaching High Value Musculoskeletal Care Through Online Simulation Cases
Abstract Number: 157

Utility of Mailed Reminders for Uveitis Screening Guidelines in Patients with Juvenile Idiopathic Arthritis
Abstract Number: 158

Quality of Referral Letters to Pediatric Rheumatology and Its Impact on Access to Care
Abstract Number: 159

Preferences and Satisfaction in a Pediatric Multi-specialty Infusion Center
Abstract Number: 160

Stepping Stones to Transition Smartly

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].